Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of drugs and vaccines. It was founded in 1891 by George Merck and is headquartered in Kenilworth, New Jersey. The company is known for its innovative research and development and has a strong commitment to corporate social responsibility.
Company Info
US58933Y1055
58933Y105
Jan 13, 1978
Highlights
$187.83B
$7.00
10.69
0.69
$63.92B
$51.75B
$27.30B
$73.31 - $131.54
$102.71
1.65%
2.12
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Merck & Co., Inc. (MRK) returned -22.88% year-to-date (YTD) and -40.16% over the past 12 months. Over the past 10 years, MRK returned 6.00% annually, underperforming the S&P 500 benchmark at 10.87%.
MRK
-22.88%
-0.52%
-19.71%
-40.16%
3.11%
6.00%
^GSPC (Benchmark)
1.30%
12.94%
1.49%
12.48%
15.82%
10.87%
Monthly Returns
The table below presents the monthly returns of MRK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.66% | -6.65% | -1.86% | -5.08% | -10.73% | -22.88% | |||||||
| 2024 | 10.79% | 5.27% | 4.43% | -2.07% | -2.85% | -0.80% | -8.62% | 4.70% | -3.49% | -9.90% | -0.66% | -1.34% | -6.26% |
| 2023 | -3.19% | -1.09% | 0.84% | 8.53% | -4.38% | 5.21% | -7.57% | 2.18% | -4.89% | -0.24% | -0.21% | 7.15% | 1.01% |
| 2022 | 6.32% | -6.01% | 8.10% | 8.09% | 3.77% | -0.12% | -2.01% | -4.45% | 1.70% | 17.51% | 8.81% | 1.42% | 49.42% |
| 2021 | -5.78% | -5.77% | 7.09% | -3.36% | 1.87% | 8.32% | -1.16% | -0.75% | -0.66% | 17.23% | -14.92% | 3.28% | 1.75% |
| 2020 | -6.06% | -10.39% | 1.33% | 3.12% | 1.74% | -3.44% | 3.76% | 6.27% | -2.01% | -9.33% | 6.89% | 2.56% | -7.20% |
| 2019 | -2.59% | 9.22% | 3.01% | -5.36% | 0.64% | 6.56% | -1.03% | 4.19% | -2.00% | 2.95% | 0.60% | 5.04% | 22.27% |
| 2018 | 5.30% | -8.49% | 1.34% | 8.08% | 1.12% | 2.75% | 8.52% | 4.13% | 4.13% | 3.76% | 7.78% | -3.02% | 39.95% |
| 2017 | 5.30% | 6.26% | -2.84% | -1.90% | 4.46% | -0.84% | -0.33% | -0.03% | 0.99% | -13.96% | 0.33% | 2.68% | -1.49% |
| 2016 | -4.07% | -0.91% | 6.30% | 3.65% | 2.59% | 3.24% | 1.82% | 7.04% | 0.12% | -5.91% | 4.21% | -3.05% | 15.05% |
| 2015 | 6.15% | -2.89% | -1.02% | 3.62% | 2.23% | -5.79% | 3.57% | -8.67% | -7.49% | 10.67% | -3.02% | 0.50% | -3.89% |
| 2014 | 5.83% | 7.59% | 0.39% | 3.15% | -1.20% | 0.74% | -1.92% | 5.94% | -0.66% | -2.26% | 4.25% | -5.27% | 16.93% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of MRK is 2, meaning it’s performing worse than 98% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Merck & Co., Inc. provided a 4.15% dividend yield over the last twelve months, with an annual payout of $3.16 per share. The company has been increasing its dividends for 20 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $3.16 | $3.12 | $2.96 | $2.80 | $2.61 | $2.37 | $2.16 | $1.90 | $1.80 | $1.77 | $1.73 | $1.69 |
Dividend yield | 4.15% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Merck & Co., Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.81 | $0.00 | $0.00 | $0.81 | |||||||
| 2024 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.81 | $3.12 |
| 2023 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.77 | $2.96 |
| 2022 | $0.00 | $0.00 | $0.69 | $0.00 | $0.00 | $0.69 | $0.00 | $0.00 | $0.69 | $0.00 | $0.00 | $0.73 | $2.80 |
| 2021 | $0.00 | $0.00 | $0.62 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.69 | $2.61 |
| 2020 | $0.00 | $0.00 | $0.58 | $0.00 | $0.00 | $0.58 | $0.00 | $0.00 | $0.58 | $0.00 | $0.00 | $0.62 | $2.37 |
| 2019 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.58 | $2.16 |
| 2018 | $0.00 | $0.00 | $0.46 | $0.00 | $0.00 | $0.46 | $0.00 | $0.00 | $0.46 | $0.00 | $0.00 | $0.52 | $1.90 |
| 2017 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.46 | $1.80 |
| 2016 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.45 | $1.77 |
| 2015 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.44 | $1.73 |
| 2014 | $0.42 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.43 | $1.69 |
Dividend Yield & Payout
Dividend Yield
Merck & Co., Inc. has a dividend yield of 4.15%, which is quite average when compared to the overall market.
Payout Ratio
Merck & Co., Inc. has a payout ratio of 40.56%, which is quite average when compared to the overall market. This suggests that Merck & Co., Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Merck & Co., Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Merck & Co., Inc. was 68.62%, occurring on Mar 9, 2009. Recovery took 1239 trading sessions.
The current Merck & Co., Inc. drawdown is 41.45%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -68.62% | Dec 29, 2000 | 2057 | Mar 9, 2009 | 1239 | Feb 7, 2014 | 3296 |
| -47.25% | Jan 6, 1992 | 408 | Aug 13, 1993 | 494 | Jul 28, 1995 | 902 |
| -43.44% | Jun 25, 2024 | 223 | May 14, 2025 | — | — | — |
| -36.5% | Mar 23, 1999 | 243 | Mar 7, 2000 | 160 | Oct 23, 2000 | 403 |
| -35.02% | Jun 10, 1981 | 299 | Aug 13, 1982 | 236 | Jul 20, 1983 | 535 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Merck & Co., Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Merck & Co., Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 4.2% positive surprise.
Valuation
The Valuation section provides an overview of how Merck & Co., Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for MRK, comparing it with other companies in the Drug Manufacturers - General industry. Currently, MRK has a P/E ratio of 10.7. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for MRK compared to other companies in the Drug Manufacturers - General industry. MRK currently has a PEG ratio of 0.7. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MRK relative to other companies in the Drug Manufacturers - General industry. Currently, MRK has a P/S ratio of 2.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MRK in comparison with other companies in the Drug Manufacturers - General industry. Currently, MRK has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |